The ideal approach to the treatment of the hypotension associated with anaphylaxis is an old debate that has remained unresolved through the decades. Is adrenaline alone the best therapy or should colloid or crystalloid be used in combination with adrenaline? This study by Tajima et al 1 uses an animal model to address this fundamental question. Does it provide us with any direction in this regard? Yes… and no.
To answer this question emphatically would be impractical and likely unethical, as it would require a prospective study of anaphylactic cases in humans. To be able to collect the data required in terms of haemodynamics as well as biochemical markers of resuscitation, monitoring would need to be in situ before the reaction. The environment in which these conditions are most readily met in a hospital environment is the operating theatre.
Such a study would be made impossible by the sheer number of patients needing to be studied. If an incidence of one case of anaphylaxis per 10,000 anaesthetics is assumed, two million patients would need to be recruited to have 100 patients in the crystalloid and colloid arms of the study, assuming that this would allow sufficient power for the study results to be useful. A cohort of adrenaline only would certainly not pass ethics appraisal. Confounding factors such as inability to match for age, comorbidities, anaesthetic and surgical techniques and difficulties with blinding of treating anaesthetists all make such a trial logistically impossible.
It is important to understand that in some cases of anaphylaxis in humans, rapid fluid extravasation is prominent, leading to a 35% to 70% decrease in circulating blood volume within 10 minutes 2,3,4 . A classic echocardiographic finding in such patients is a hyperdynamic but empty left ventricle. This combined with the vasodilatory and negative inotropic effects of most anaesthetic agents can rapidly lead to cardiac arrest. In other cases, hypotension is mild or even absent. Approximately 4.5% cases of perioperative anaphylaxis present with bronchospasm only 5 . As if it were necessary, a further confounding factor is the propensity of some colloids to cause anaphylaxis in their own right.
International guidelines have followed expert opinion in the absence of any firm evidence to guide them. They have historically provided anaesthetists differing instruction on type and volume of fluid to be administered during the treatment of anaphylaxis during anaesthesia. The French experts 6 recommend that "vascular volume is replenished with crystalloids of 20ml/kg and colloids of 10ml/kg. A total of 60ml/kg may be needed". The Association of Anaesthetists of Great Britain and Ireland 7 recommend "Administer saline 0.9% or lactated Ringer's solution at a high rate via an intravenous cannula of an appropriate gauge (large volumes may be required)" and regarding crystalloid versus colloid that "There is no evidence that one is better than the other. If an IV colloid has already been given to the patient before the appearance of clinical signs of anaphylaxis, it should be discontinued and either replaced by crystalloid or replaced by a colloid of a different class; e.g. replace a gelatin-based colloid with a starch-based colloid". The most recent Scandinavian Guidelines 8 also suggest that either type of fluid is appropriate. Fluid therapy is important to counteract the large fluid shifts associated with vasodilatation and capillary leakage, and in severe cases, several litres of crystalloid/colloid are needed.
This study by Tajima et al 1 uses a rat model where anaphylaxis is created, then comparisons made between treatment with adrenaline only and with combinations of hypertonic saline, isotonic saline and a colloidal starch solution. Small numbers of rats were used in the study (only five per arm), which may have limited the ability of this study to show differences between the approaches. It is also important to note that differing volumes of each fluid were administered allowing for theoretical differences in volume expansion capabilities.
Despite the limitations of this study, it supports some basic and very important conclusions. First, this data would suggest that hypotension associated with anaphylaxis is best treated with a combination of intravenous volume replacement as well as Anaesth Intensive Care 2013; 41: 701-703 Editorial Crystalloid or colloid treatment of hypotension during anaphylaxis associated with anaesthesia -Are we there yet? adrenaline. Equally importantly, it shows that the theoretical promise of relatively fast intravenous volume replacement with hypertonic saline (that may be expected to draw fluid from the interstitium back into the intravascular space) is likely to create a dangerous hyperchloraemic acidosis.
Also importantly, this study does not show a clear difference between the colloid used here (hydroxyethyl starch, or HES) and isotonic saline. Both were similarly effective in combination with adrenaline at treating the hypotension associated with anaphylaxis in the rat. There was a non-significant but slightly reduced time to restoration of target mean arterial pressure in the HES group compared to the isotonic saline group. It is possible that if the same volume of both of these fluids was used instead of the 30ml/kg of isotonic saline versus the 20ml/kg of HES, the result may have been clearer. This would fit with what we know about the greater theoretical ability of colloids to restore intravascular volume compared to crystalloids.
HES was chosen in this study as gelatin based colloids have been implicated in a substantial number of cases of anaphylaxis 9, 10 . Recently, concerns have arisen about the safety of HES, and the result has been the suspension of approval or restriction of use of HES in many regions, including the European Union and the United States of America. In Australia the Therapeutic Goods Administration 11 has commenced a full risk/benefit analysis but issued advice suggesting that "Use in critically ill patients should only be considered if other therapies have failed, the lowest possible dose is chosen, and the benefits outweigh the risk". As such, HES therapy, despite performing well in this animal model, would not be advisable. It may be that the performance of HES is translatable to colloid therapy in general. The authors have suggested that albumin may be a possible alternative colloid. A drawback with the administration of albumin in severe anaphylactic shock is a practical one -the product is presented in a glass bottle not amenable to use with rapid infusion devices. Rapid administration usually requires a dedicated person to manually squeeze a pump administration set.
Recently, new guidelines for the treatment of anaesthetic related anaphylaxis have been introduced in Australia and New Zealand by the Australian and New Zealand Anaesthetic Allergy Group 12 . This recently formed group has members from Anaesthetic and Immunology specialties. The Australian and New Zealand Anaesthetic Allergy Group guidelines call for the administration of adrenaline and fluid for the treatment of hypotension associated with anaphylaxis. In keeping with the lack of evidence (level 4) to recommend either colloid or crystalloid, these guidelines allow for either type of fluid to be used. The initial bolus in the presence of hypotension should be 20ml/kg, repeated if necessary and escalating to 50ml/kg for severe refractory hypotension. It should be remembered that colloids (particularly if gelatin based) may be the cause of the anaphylactic reaction, so sense dictates that any colloid running should be ceased and substituted for crystalloid or a non-related colloid.
A variety of resources have been developed by this group, including immediate and refractory treatment guidelines as well as instructions for poststabilisation management. The presentation of these guidelines have been honed by human factor specialists and simulation studies. These resources are available as PDF downloads from www.anzaag. com. There are also instructions on how to establish an 'anaphylaxis box' which will contain a copy of these guidelines, the correct blood vials for mast cell tryptase analysis and further information for both anaesthetists and patients. Their website also allows identification and contact details of local anaesthetic allergy testing centers throughout Australia and New Zealand.
So, is there sufficient evidence to answer the age-old question of how best to treat hypotension associated with anaphylaxis? The answer is not entirely, but there is evidence to strongly suggest that fluid administration is important in addition to adrenaline administration. There is also some extra evidence now to support the theoretical benefit that colloids have in replenishing intravascular volume. Some additional clarification on this topic would be achieved by a larger trial comparing albumin with isotonic saline to treat anaphylaxis. While such a trial is impractical in humans, further animal studies may be possible. In the interim, it is important to remember that if colloid is being administered at the time of the anaphylactic reaction it should be discontinued and replaced with a non-related fluid (colloid or crystalloid).
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